Literature DB >> 11533400

Delays in adopting evidence-based dosages of conventional antipsychotics.

M Valenstein1, L Copeland, R Owen, F Blow, S Visnic.   

Abstract

By the 1980s, strong research evidence had emerged supporting the use of moderate doses of conventional antipsychotics-between 300 and 1,000 mg of chlorpromazine equivalent daily. We conducted a cross-sectional study of dosages of antipsychotics prescribed for 936 veterans with schizophrenia in 14 facilities between 1991 and 1995. Only 52 percent of these patients received prescriptions for recommended dosages; dosages were below the recommended range for 20 percent and above the range for 28 percent. African Americans were more likely than others to have received high dosages. These data suggest that there was considerable delay in the adoption of evidence-based dosing of conventional antipsychotics. Efforts must be made to transfer research findings more rapidly into practice.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11533400     DOI: 10.1176/appi.ps.52.9.1242

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  5 in total

Review 1.  Emerging empirical evidence on the ethics of schizophrenia research.

Authors:  Laura B Dunn; Philip J Candilis; Laura Weiss Roberts
Journal:  Schizophr Bull       Date:  2005-10-19       Impact factor: 9.306

2.  [Guidelines based on decision support software. Quality management in neurological outpatient schizophrenia treatment].

Authors:  B Janssen; R Menke; F Pourhassan; D Gessner-Ozokyay; R Peters; W Gaebel
Journal:  Nervenarzt       Date:  2006-05       Impact factor: 1.214

3.  Predictors of antipsychotic medication change.

Authors:  Michael J Sernyak; Douglas Leslie; Robert Rosenheck
Journal:  J Behav Health Serv Res       Date:  2005 Jan-Mar       Impact factor: 1.505

4.  High-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies.

Authors:  Kang Sim; Hsin Chuan Su; Senta Fujii; Shu-Yu Yang; Mian-Yoon Chong; Gabor Ungvari; Tianmei Si; Yan Ling He; Eun Kee Chung; Yiong Huak Chan; Naotaka Shinfuku; Ee Heok Kua; Chay Hoon Tan; Norman Sartorius
Journal:  Br J Clin Pharmacol       Date:  2009-01       Impact factor: 4.335

Review 5.  Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations.

Authors:  Giuseppe Rossi; Sonia Frediani; Roberta Rossi; Andrea Rossi
Journal:  BMC Psychiatry       Date:  2012-08-21       Impact factor: 3.630

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.